CD24 and breast carcinoma: A multiplex immunohistochemistry (mIHC) was performed on tumor specimens from ER+ breast cancer patients and based on the expression levels of C4-specific markers (MUCL1 and CD24); these cases were stratified into C4-high invasive and C4-low invasive subgroups (Figure 4B).